American Society of Hirudotherapy

Comparative study of hirustasin superfamily gene expression in two medicinal leeches

Basic science / genomics published in Genes (2025)

Last Updated: June 18, 2026Reviewed by: ASH Editorial Board
Research article — evidence reviewArticle reference
Evidence: Observational studyGenomics & ProteomicsSalivary PharmacologySun et al. · Genes, 2025

Abstract

BACKGROUND/OBJECTIVES: Leeches constitute a pharmacologically significant animal group in traditional medicine due to their antithrombotic peptides, which include numerous members of the hirustasin gene superfamily. However, a comparative expression profile of this pharmaceutically important family across different leech species is lacking. METHODS: This study conducted a comparative transcriptomic analysis of hirustasin gene superfamily expression in the hematophagous leech Hirudinaria manillensis and the non-hematophagous leech Whitmania pigra. RESULTS: The total expression of the hirustasin gene superfamily, quantified as transcripts per million (TPM), showed no significant difference (p = 0.237) between H. manillensis (11,802.60 ± 1596.59) and W. pigra (8623.12 ± 965.96). However, both species exhibited pronounced intergenic expression heterogeneity. Five dominantly expressed genes (TPM > 1000) in H. manillensis and three in W. pigra were identified, collectively comprising 81% and 62% of the total hirustasin gene superfamily expression per species, respectively. Critically, the dominantly expressed genes exhibited no phylogenetic correspondence between species. Integrating expression profiles with phylogenetic reconstruction identified five high-potential candidate genes: poecistasin_Hman2, hirustasin_like_Hman01, hirustasin_like_Hman11, guamerin_Wpig, and bdellastasin_Wpig. Population-level analysis revealed marked population-specific expression patterns in H. manillensis, contrasting with minimal inter-population divergence in W. pigra. Nevertheless, geographically distinct populations of both species showed significant variation in the expression of their respective dominantly expressed genes. CONCLUSIONS: These findings provide a set of high-priority candidate genes and insights into their expression characteristics, serving as a starting point for subsequent functional validation and, when integrated with other screening methods, for future antithrombotic drug discovery.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal ArticleComparative Study
Indexed MeSH termsAnimalsLeechesTranscriptomeGene Expression ProfilingPhylogenyMultigene Family

Summary

Comparative gene-expression study of hirustasin superfamily in two medicinal-leech species characterizing tissue-specific bioactive-compound expression patterns.

Why This Matters for Hirudotherapy

This comparative transcriptomic study profiled expression of the hirustasin antithrombotic-peptide gene superfamily in two leeches, the blood-feeding Hirudinaria manillensis and the non-blood-feeding Whitmania pigra, finding no significant difference in total superfamily expression (p = 0.237) but marked gene-to-gene and population-level heterogeneity, and nominating five high-potential candidate genes (including poecistasin_Hman2 and bdellastasin_Wpig) for further work. For hirudotherapy it strengthens the scientific spine of the leech-secretome drug-discovery narrative: the antithrombotic value of leeches lies in defined peptide families that can be mapped, prioritized, and eventually validated as drug leads. As a preclinical genomics/expression analysis, it identifies candidates only and performs no functional, animal, or clinical testing; the authors themselves frame the findings as a starting point for subsequent functional validation and future antithrombotic drug discovery, not as evidence of clinical activity.

Citation

Comparative study of hirustasin superfamily gene expression in two medicinal leeches.

Sun et al. · Genes, 2025

Added to ASH library: May 27, 2026 · Site last updated: June 18, 2026

This website provides educational information and does not constitute medical advice, diagnosis, or treatment recommendations. Medicinal leech therapy carries clinically meaningful risks and should be performed only by qualified clinicians under institutionally approved protocols. FDA 510(k) clearance for medicinal leeches is limited to specific indications; investigational and off-label discussions are labeled accordingly. For patient-specific guidance, consult a qualified healthcare provider.